CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
SLIDE-HCC: Phase II trial of STRIDE (durvalumab + tremelimumab) + lenvatinib vs STRIDE in patients with unresectable hepatocellular carcinoma
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Docetaxel and Hormone Treatment compared to Hormone Treatment alone in people with Metastatic Castration Sensitive Prostate Cancer and Less than Optimal PSA Response (TRIPLE-SWITCH)
OlympiA: A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.
The Toronto International Sarcoma Symposium 2021 (virtual format) is just around the corner!
This multidisciplinary symposium will be held on April 09, 2021, and includes speakers and participants from Canada as well as from the International Sarcoma community. The keynote speakers are Dr. Andrew Wagner (Dana Farber) and Dr. David Kirsch (Duke). The one day symposium will feature Clinical and Translational Research among other topics, please see the program page for details.
The CCTG CO29 (AGITG CTDNA-08) - Circulating Tumor DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer: A Multi-centre Phase II/III Randomised Controlled Study (DYNAMIC III) has been centrally activated.
CCTG is hiring and looking for a Manager, Office of Compliance and Oversight (OCO) and a Quality Leader, Office of Clinical Trials Management (OCTM) to join our team at the central operations office at Queen's University.
CCTG is delighted to announce that Dr. Alexander Wyatt has become the new Correlative Sciences Committee Chair for the CCTG GU disease site committee.
Dr. Wyatt is an Assistant Professor in Urologic Sciences at the University of British Columbia, a Senior Research Scientist at the Vancouver Prostate Centre, and Scientist at the BC Cancer Genome Sciences Centre. He has a PhD in genetics (University of Oxford), and now specializes in human genitourinary cancer genomics and bio informatics
Meet Martina Wood a breast cancer survivor and a member of the CCTG breast committee. Our teams are proud to work with volunteers like Martina who ensure the patient voice is part of our clinical trial development.
The Canadian Cancer Trials Group (CCTG), at Queen’s University, asks and finds evidence-based answers to critical questions about the best treatment options for the 225,000 Canadians diagnosed with cancer each year. Innovations proven to be effective through CCTG led clinical trials have set new standards of care that guide treatment decisions for patients today and tomorrow: curing disease, preventing recurrence, saving lives, and improving quality of life. See full article here.
A paper has recently been published in Current Oncology outlining the incorporation of patient engagement in the development of clinical trial at the Canadian Cancer Trials Group (CCTG).
